London, February 25, 2026 (Proactive) -- GSK has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, adding a clinical-stage pulmonary hypertension therapy to its pipeline. The company believes the drug could offer a safer alternative to existing treatments, which are often limited by bleeding complications. The global pulmonary hypertension market is projected to reach $18 billion by 2032. The centerpiece of the deal is HS235, an activin signaling inhibit

Boca Raton, FL, February 18, 2026 (Globe Newswire) -- LIXTE Biotechnology Holdings, Inc., a clinical-stage oncology company developing small-molecule cancer therapies and radiotherapy technologies, announced the appointment of Sidney Braun as Chief Executive Officer of its European subsidiary, Liora Technologies Europe Ltd.. Braun brings more than two decades of healthcare operational and strategic experience and previously played a key role in establishing Liora and facili

Waltham, MA, February 18, 2026 (Business Wire) -- Korsana Biosciences announced it has emerged from stealth mode with $175 million in total funding to advance novel therapies for neurodegenerative diseases, initially focusing on Alzheimer’s disease. The financing includes a $25 million seed round in 2024 led by Fairmount and Venrock Healthcare Capital Partners, followed by a $150 million Series A in September 2025 co-led by Wellington Management and TCGX, with participation

Paris, February 12, 2026 (Sanofi) -- Sanofi has named Belen Garijo as its next Chief Executive Officer, following the Board’s decision not to renew Paul Hudson’s mandate. Hudson will step down on February 17, 2026, after six years leading the company’s strategic transformation. Garijo will officially assume the CEO role after the Annual General Meeting on April 29, 2026, subject to shareholder approval of her nomination to the Board. During the interim period, Olivier Charm

Washington, February 17, 2026 (PRNewswire) -- Danaher Corporation announced it has signed a definitive agreement to acquire Masimo Corporation, a leader in pulse oximetry and advanced patient monitoring technologies, in an all-cash deal valued at approximately $9.9 billion, including assumed debt. Under the agreement, Danaher will pay $180 per share in cash, representing a transaction multiple of roughly 18x estimated 2027 EBITDA, or 15x including expected synergies. Masimo

Franklin Lakes, NJ, February 9, 2026 (PRNewswire) -- BD said it has completed the spin-off of its Biosciences & Diagnostic Solutions business and combined it with Waters Corporation, finalizing the previously announced transaction. At closing, BD shareholders received Waters shares representing 39.2% of the combined company (fully diluted), and BD said the business was valued at $18.8B based on Waters’ Feb. 6, 2026 closing price. BD also said it plans to deploy $2B toward a

Boston and Toronto, February 10, 2026 (Globe Newswire) -- Helus Pharma named Michael Cola Chief Executive Officer, effective immediately, as the company shifts into a “scale and execution” phase. Cola previously led Shire’s Specialty Pharmaceutical business and brings 30+ years across neuroscience, rare disease, and specialty pharma, with experience spanning late-stage development and global commercialization. The company said the timing aligns with upcoming milestones, inc

Millbrae, CA, February 4, 2026 (Globe Newswire) -- Eikon Therapeutics set the price for an upsized initial public offering of 21,177,600 common shares at $18.00 each and granted underwriters a 30-day option to buy up to 3,176,640 additional shares. The company expects gross proceeds of roughly $381 million before fees and expenses (excluding any proceeds from the option), with trading anticipated to begin on Feb. 5, 2026, subject to customary closing conditions. Read full a

Chelmsford, M A, February 4, 2026 (ZOLL) -- ZOLL Medical (an Asahi Kasei company) appointed Eric Knudsen as Chief Executive Officer, effective April 1, 2026. Knudsen will succeed Jon Rennert, who led ZOLL for the past 10 years and will move into the role of Executive Chairman of the Board. ZOLL highlighted Knudsen’s nearly 30 years in medtech, including leading corporate development at ZOLL and most recently serving as President of ZOLL Itamar, where he oversaw significant

Indianapolis and Watertown, MA, February 9, 2026 (PRNewswire) -- Eli Lilly signed a definitive agreement to acquire Orna Therapeutics, adding a circular RNA + lipid nanoparticle platform designed to engineer immune cells inside the body rather than via traditional ex vivo manufacturing. Read full article here .

San Francisco, CA, January 22, 2026 (Business Wire) -- Mendra launched with an oversubscribed $82 million Series A financing to acquire, develop, and commercialize therapies for rare diseases with high unmet need. The round was co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC. The company plans to leverage artificial intelligence to accelerate patient identification, clinical trial enrollment, and global commercialization as it build

Kingston, NY, January 27, 2026 (PRNewswire) -- Millrock Technology has appointed Tom Hochuli as Chief Executive Officer, bringing more than 30 years of leadership across life sciences, medical devices, and biologics manufacturing. Hochuli joins at a pivotal growth stage and is expected to strengthen Millrock’s position as a trusted innovator in advanced freeze-drying and processing technologies for pharma and biotech customers. His background includes leading operational tr

Minneapolis & Brisbane, January 22, 2026 (Globe Newswire) -- Anteris Technologies Global Corp. announced a $90 million strategic investment from Medtronic, bringing total gross proceeds to $320 million when combined with a concurrent underwritten equity offering. The funding will support execution of Anteris’ global pivotal PARADIGM trial and accelerate progress toward worldwide commercialization of its DurAVR® transcatheter heart valve for aortic stenosis. Company leaders

Princeton, NJ, January 28, 2026 (Business Wire) -- Taiho Oncology appointed Peter Melnyk as President and Chief Executive Officer, effective immediately, following the retirement of Tim Whitten after 13 years of leadership. Melnyk brings more than three decades of experience in oncology commercialization across pharma, biotech, and medical devices, most recently serving as Chief Commercial Officer at Alpha Tau Medical. His appointment comes as Taiho Oncology builds on recen

Berkeley Heights, NJ, January 22, 2026 (Globe Newswire) -- Corxel Pharmaceuticals closed a Series D1 financing of up to $287 million to accelerate development of its cardiometabolic portfolio, led by the oral small-molecule GLP-1 receptor agonist CX11. The proceeds will fund ongoing U.S. Phase 2 studies in obesity and overweight patients, planned global Phase 2 trials in type 2 diabetes, early Phase 3 preparations, and additional programs spanning acute ischemic stroke and

Menlo Park, CA, January 12, 2026 (Business Wire) -- Inquis Medical closed a $75 million Series C financing from an undisclosed strategic investor to accelerate nationwide commercial expansion of its AVENTUS thrombectomy system and advance its next-generation pipeline. The raise follows a pivotal year in which the company transitioned to a commercial-stage organization, expanded regulatory clearance for pulmonary embolism, and published positive pivotal trial data demonstrat

Billerica, MA, January 8, 2026 (Business Wire) -- Quanterix Corporation appointed Everett Cunningham as President and Chief Executive Officer, effective January 19, 2026, as part of a planned leadership transition. Cunningham joins from Illumina, where he served as Chief Commercial Officer, following earlier commercial leadership roles at Exact Sciences, Quest Diagnostics, GE Healthcare, and Pfizer. The company said it expects to exceed its full-year 2025 revenue and cash g

Boston, MA, January 9, 2026 (PRNewswire) -- Haemonetics Corporation announced the acquisition of Vivasure Medical Limited, a Galway-based medtech company developing next-generation percutaneous vessel closure technology. Vivasure’s PerQseal® Elite system uses a fully bioabsorbable, suture-free patch to close large-bore access sites and has already secured CE Mark approval in Europe, with a U.S. FDA PMA submission completed in 2025. The deal includes €100 million in upfront

Melville, NY, January 12, 2026 (Business Wire) -- Henry Schein, Inc. announced the appointment of Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026, at which point he will also join the Board of Directors. Lowery succeeds Stanley M. Bergman, who will step down after 35 years as CEO and continue as Chairman to support a smooth leadership transition. Lowery brings more than 20 years of healthcare distribution and operational leadership experience, most r

Indianapolis, IN, January 7, 2026 (PR Newswire) -- Eli Lilly and Company announced it will acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion, expanding its presence in inflammatory-mediated diseases. The deal brings Ventyx’s clinical-stage portfolio of oral small molecules, including NLRP3 inhibitors designed to address chronic inflammation across cardiometabolic, neurodegenerative, and autoimmune conditions. Lilly will pay $14.00 pe